 | Up a level |
Schuler, A; Huser, J; Schmid, S; Schär, S; Scherz, A; Gautschi, O; Mauti, L; von Briel, T; Waibel, C; Wannesson, L; Pankovics, J; Mark, M T; Rothschild, S I; Addeo, A; Janthur, W D; Siano, M; Boos, L; Britschgi, C; Früh, M (2024). Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study. Lung cancer, 187(107427), p. 107427. Elsevier 10.1016/j.lungcan.2023.107427
Digklia, A; Kollár, A; Dietrich, D; Kronig, M N; Britschgi, C; Rordorf, T; Joerger, M; Krasniqi, F; Metaxas, Y; Colombo, I; Ribi, K; Rothermundt, C (2024). SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial. European journal of cancer, 197(113470), p. 113470. Elsevier 10.1016/j.ejca.2023.113470
Schmid, S; Jochum, W; Padberg, B; Demmer, I; Mertz, K D; Joerger, M; Britschgi, C; Matter, M S; Rothschild, S I; Omlin, A (2022). How to read a next-generation sequencing report-what oncologists need to know. ESMO open, 7(5), p. 100570. BMJ 10.1016/j.esmoop.2022.100570
Britschgi, C; Rizzi, M; Grob, T J; Tschan, M P; Hügli, B; Reddy, V A; Andres, Anne Catherine; Torbett, B E; Tobler, A; Fey, M F (2006). Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1. Oncogene, 25(14), pp. 2030-2039. Basingstoke, UK: Nature Publishing Group 10.1038/sj.onc.1209240
Joerger, M; Metaxas, Y; Schmitt, AM; Koeberle, D; Zaman, K; Betticher, D; Mach, N; Renner, C; Mark, M; Petrausch, U; Caspar, C; Britschgi, C; Taverna, C; Zenger, F; Mingrone, W; Schulz, J; Kopp, C; Hayoz, S; Stathis, A and von Moos, R (2020). Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA) (Unpublished). In: Virtual ESMO 2020.
